Peking University Cancer Hospital & Institute
bjcancer.orgTotal trials
245
Active
103
Phase 3
10
Total enrollment
102,419
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 103 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Traditional Chinese medicine (TCM) hand and foot baths | — | — | — | — | — | 1 | |
| Methylcobalamin | — | — | — | — | — | 1 | |
| Dose Escalation | — | — | — | — | — | 1 | |
| Camrelizumab | — | — | — | — | 5 | ||
| Sunitinib | — | — | — | — | 2 | ||
| Camrelizumab ＋Immunotherapy | — | — | — | — | — | 1 | |
| camrelizumab+apatinib+TMZ | — | — | — | — | — | 1 | |
| camrelizumab+apatinib | — | — | — | — | — | 1 | |
| CapeOX | — | — | — | — | — | 1 | |
| Fruquintinib and Tislelizumab combined with mCapeOX | — | — | — | — | — | 1 | |
| Vorolanib Tablets+Everolimus | — | — | — | — | — | 1 | |
| KN046 | — | — | — | — | — | 4 | |
| Carboplatin | — | — | — | — | 4 | ||
| Bevacizumab | — | — | — | — | — | 5 | |
| Tislelizumab | — | — | — | — | 4 | ||
| Cisplatin | — | — | — | — | 3 | ||
| SHR-A1811 | — | — | — | — | — | 2 | |
| Iparomlimab/Tuvonralimab | — | — | — | — | — | 2 | |
| Pemetrexed | — | — | — | — | 2 | ||
| Oxaliplatin | — | — | — | 8 | |||
| Capecitabine | — | — | — | — | 7 | ||
| Regorafenib | — | — | — | — | 4 | ||
| Pyrotinib | — | — | — | — | 2 | ||
| Pertuzumab | — | — | — | — | 2 | ||
| Combination product: Trastuzumab + Pertuzumab | — | — | — | — | 2 | ||
| Apatinib | — | — | — | — | — | 4 | |
| apatinib mesylate | — | — | — | — | — | 3 | |
| Axitinib | — | — | — | — | 2 | ||
| Niraparib | — | — | — | — | 2 | ||
| Ensartinib | — | — | — | — | — | 2 | |
| CDK4/6 inhibitor | — | — | — | — | — | 2 | |
| PD-(L)1 inhibitor | — | — | — | — | — | 1 | |
| Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy | — | — | — | — | — | 1 | |
| Perioperative treatment | — | — | — | — | — | 1 | |
| KN026 | — | — | — | — | — | 1 | |
| XELOX | — | — | — | — | — | 1 | |
| herombopag | — | — | — | — | — | 1 | |
| QL1706 Plus Celecoxib Group | — | — | — | — | — | 1 | |
| Vebreltinib combined with Furmonertinib | — | — | — | — | — | 1 | |
| chidamide and golidocitinib | — | — | — | — | — | 1 |
63 more active programs hidden
Next readouts
- 2023-12-31
- 2024-03-01
- 2024-11-30
- 2024-12-01
- 2025-05-01
- 2025-06-30
- 2025-07-07
- 2025-12-20
- 2025-12-30
- 2025-12-31
Top conditions
- Melanoma18
- Breast Cancer13
- Rectal Cancer12
- Gastric Cancer9
- Solid Tumor8
- Colorectal Cancer7
- Breast Neoplasms6
- Neoplasm Metastasis6
Frequently asked questions about Peking University Cancer Hospital & Institute
- How many clinical trials does Peking University Cancer Hospital & Institute have on ClinicalTrials.gov?
- Peking University Cancer Hospital & Institute is listed as the lead sponsor on 245 clinical trials in ClinicalTrials.gov, 103 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Peking University Cancer Hospital & Institute's trials are in Phase 3?
- 10 of Peking University Cancer Hospital & Institute's trials are in Phase 3, spread across 103 active drug programs.
- What therapeutic areas does Peking University Cancer Hospital & Institute focus on?
- Peking University Cancer Hospital & Institute's most-studied conditions on ClinicalTrials.gov are Melanoma, Breast Cancer, Rectal Cancer, Gastric Cancer, Solid Tumor.
- When are Peking University Cancer Hospital & Institute's next clinical trial readouts?
- Peking University Cancer Hospital & Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma”, expected around 2023-12-31.